Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

NCT03470311 is registered in ClinicalTrials.gov with McMaster University as lead sponsor.

NCT NCT03470311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03470311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies
Lead sponsor
McMaster University
Phase
Phase 3
Overall status
Completed
Start date
April 26, 2018
Completion date
November 30, 2022
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe prednisone dependent eosinophilic asthma